Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2021; 47(07): 745-753
DOI: 10.1055/s-0041-1735258
DOI: 10.1055/s-0041-1735258
Editorial
New STH (2020) Impact Factor, Most Highly Cited Papers, and Other Journal Metrics
![](https://www.thieme-connect.de/media/sth/202107/lookinside/thumbnails/10-1055-s-0041-1735258_02933-1.jpg)
This Editorial marks a slight deviation from our standard editorial, typically announcing our newest Impact Factor and other journal metrics as part of our yearly welcome editorial. This change has been initiated in recognition of the move away from print publication toward an increased online presence. Accordingly, this Editorial is being published before our standard yearly Welcome Editorial, which always publishes with the first issue of the year. With this Editorial, I have also decided to share additional journal metrics with the readership.
Publication History
Article published online:
04 October 2021
© 2021. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part I. Semin Thromb Hemost 2020; 46 (07) 757-762
- 2 Favaloro EJ, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19): part II. Semin Thromb Hemost 2021; 47 (04) 333-337
- 3 Favaloro EJ. The journal impact factor: don't expect its demise any time soon. Clin Chem Lab Med 2009; 47 (11) 1319-1324
- 4 Favaloro EJ. Measuring the quality of journals and journal articles: the impact factor tells but a portion of the story. Semin Thromb Hemost 2008; 34 (01) 7-25
- 5 Laridan E, Martinod K, De Meyer SF. Neutrophil extracellular traps in arterial and venous thrombosis. Semin Thromb Hemost 2019; 45 (01) 86-93
- 6 Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost 2018; 44 (01) 20-29
- 7 Kumar KR, Cowley MJ, Davis RL. Next-generation sequencing and emerging technologies. Semin Thromb Hemost 2019; 45 (07) 661-673
- 8 Marongiu F, Mameli A, Grandone E, Barcellona D. Pulmonary thrombosis: a clinical pathological entity distinct from pulmonary embolism?. Semin Thromb Hemost 2019; 45 (08) 778-783
- 9 Lippi G, Gosselin R, Favaloro EJ. Current and emerging direct oral anticoagulants: state-of-the-art. Semin Thromb Hemost 2019; 45 (05) 490-501
- 10 DeLoughery EP, Olson SR, Puy C, McCarty OJT, Shatzel JJ. The safety and efficacy of novel agents targeting factors XI and XII in early phase human trials. Semin Thromb Hemost 2019; 45 (05) 502-508
- 11 Lippi G, Favaloro EJ. Venous and arterial thromboses: two sides of the same coin?. Semin Thromb Hemost 2018; 44 (03) 239-248
- 12 Kwaan HC, Lindholm PF. Fibrin and fibrinolysis in cancer. Semin Thromb Hemost 2019; 45 (04) 413-422
- 13 Russo V, Rago A, Papa AA. et al. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with malignancy: clinical practice experience in a single institution and literature review. Semin Thromb Hemost 2018; 44 (04) 370-376
- 14 Arachchillage DRJ, Passariello M, Laffan M. et al. Intracranial hemorrhage and early mortality in patients receiving extracorporeal membrane oxygenation for severe respiratory failure. Semin Thromb Hemost 2018; 44 (03) 276-286
- 15 Tillman B, Gailani D. Inhibition of factors XI and XII for prevention of thrombosis induced by artificial surfaces. Semin Thromb Hemost 2018; 44 (01) 60-69
- 16 Konstantinidi A, Sokou R, Parastatidou S. et al. Clinical application of thromboelastography/thromboelastometry (TEG/TEM) in the neonatal population: a narrative review. Semin Thromb Hemost 2019; 45 (05) 449-457
- 17 Radin M, Cecchi I, Roccatello D, Meroni PL, Sciascia S. Prevalence and thrombotic risk assessment of anti-β2 glycoprotein I domain I antibodies: a systematic review. Semin Thromb Hemost 2018; 44 (05) 466-474
- 18 Russo V, Attena E, Mazzone C. et al. Nonvitamin K antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves/prior surgical valve repair: a multicenter clinical practice experience. Semin Thromb Hemost 2018; 44 (04) 364-369
- 19 Dahlbäck B. Vitamin K-dependent protein s: beyond the protein C pathway. Semin Thromb Hemost 2018; 44 (02) 176-184
- 20 Hunt BJ. Hemostasis at extremes of body weight. Semin Thromb Hemost 2018; 44 (07) 632-639
- 21 Sorrentino S, Giustino G, Moalem K, Indolfi C, Mehran R, Dangas GD. Antithrombotic treatment after transcatheter heart valves implant. Semin Thromb Hemost 2018; 44 (01) 38-45
- 22 Russo V, Bottino R, Rago A. et al. Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants—a systematic review. Semin Thromb Hemost 2019; 45 (02) 205-214
- 23 van Asten I, Schutgens REG, Urbanus RT. Toward flow cytometry based platelet function diagnostics. Semin Thromb Hemost 2018; 44 (03) 197-205
- 24 Harenberg J, Schreiner R, Hetjens S, Weiss C. Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC Dipstick. Semin Thromb Hemost 2019; 45 (03) 275-284
- 25 Gosselin RC, Marlar RA. Preanalytical variables in coagulation testing: setting the stage for accurate results. Semin Thromb Hemost 2019; 45 (05) 433-448
- 26 Rondon AMR, Kroone C, Kapteijn MY, Versteeg HH, Buijs JT. Role of tissue factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost 2019; 45 (04) 396-412
- 27 Mahajan A, Brunson A, White R, Wun T. The epidemiology of cancer-associated venous thromboembolism: an update. Semin Thromb Hemost 2019; 45 (04) 321-325
- 28 Yamaguti-Hayakawa GG, Ozelo MC. Gene therapy: paving new roads in the treatment of hemophilia. Semin Thromb Hemost 2019; 45 (07) 743-750
- 29 Kell DB, Pretorius E. To what extent are the terminal stages of sepsis, septic shock, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome actually driven by a prion/amyloid form of fibrin?. Semin Thromb Hemost 2018; 44 (03) 224-238
- 30 Croles FN, Borjas-Howard J, Nasserinejad K, Leebeek FWG, Meijer K. Risk of venous thrombosis in antithrombin deficiency: a systematic review and Bayesian meta-analysis. Semin Thromb Hemost 2018; 44 (04) 315-326
- 31 Arachchillage DRJ, Makris M. Inherited thrombophilia and pregnancy complications: should we test?. Semin Thromb Hemost 2019; 45 (01) 50-60
- 32 Favaloro EJ, Kershaw G, Mohammed S, Lippi G. How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors. Semin Thromb Hemost 2019; 45 (01) 22-35
- 33 Arachchillage DR, Laffan M. Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost 2019; 45 (06) 604-611
- 34 Tufano A, Di Minno MND, Guida A, Lembo M, Di Minno G, Galderisi M. Cardiac manifestations of antiphospholipid syndrome: clinical presentation, role of cardiac imaging, and treatment strategies. Semin Thromb Hemost 2019; 45 (05) 468-477
- 35 Sharma BK, Flick MJ, Palumbo JS. Cancer-associated thrombosis: a two-way street. Semin Thromb Hemost 2019; 45 (06) 559-568
- 36 Thachil J. The elusive diagnosis of disseminated intravascular coagulation: does a diagnosis of DIC exist anymore?. Semin Thromb Hemost 2019; 45 (01) 100-107
- 37 Lippi G, Favaloro EJ, Sanchis-Gomar F. Sudden cardiac and noncardiac death in sports: epidemiology, causes, pathogenesis, and prevention. Semin Thromb Hemost 2018; 44 (08) 780-786
- 38 Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis. Semin Thromb Hemost 2019; 45 (04) 385-395
- 39 Maiocchi S, Alwis I, Wu MCL, Yuan Y, Jackson SP. Thromboinflammatory functions of platelets in ischemia-reperfusion injury and its dysregulation in diabetes. Semin Thromb Hemost 2018; 44 (02) 102-113
- 40 Bastida JM, Benito R, Lozano ML. et al. Molecular diagnosis of inherited coagulation and bleeding disorders. Semin Thromb Hemost 2019; 45 (07) 695-707
- 41 Santoro C, Quintavalle G, Castaman G. et al. Inhibitors in hemophilia B. Semin Thromb Hemost 2018; 44 (06) 578-589
- 42 Mege D, Aubert M, Lacroix R, Dignat-George F, Panicot-Dubois L, Dubois C. Involvement of platelets in cancers. Semin Thromb Hemost 2019; 45 (06) 569-575
- 43 Hoffman M. The tissue factor pathway and wound healing. Semin Thromb Hemost 2018; 44 (02) 142-150
- 44 Walsh M, Moore EE, Moore H. et al. Use of viscoelastography in malignancy-associated coagulopathy and thrombosis: a review. Semin Thromb Hemost 2019; 45 (04) 354-372
- 45 Koh CY, Modahl CM, Kulkarni N, Kini RM. Toxins are an excellent source of therapeutic agents against cardiovascular diseases. Semin Thromb Hemost 2018; 44 (07) 691-706
- 46 Molhoek JE, de Groot PG, Urbanus RT. The lupus anticoagulant paradox. Semin Thromb Hemost 2018; 44 (05) 445-452
- 47 Favaloro EJ. 2020 Eberhard F. Mammen Award Announcements: part I-most popular articles. Semin Thromb Hemost 2020; 46 (04) 383-392
- 48 Favaloro EJ. 2021 Eberhard F. Mammen Award Announcements: part I-most popular articles. Semin Thromb Hemost 2021; 47 (05) 467-476
- 49 Favaloro EJ. Welcome to seminars in thrombosis & hemostasis 2021-new (2019) impact factor and most highly cited papers. Semin Thromb Hemost 2021; 47 (01) 1-5
- 50 Favaloro EJA. 2018 update on the editorial and publication policy of seminars in thrombosis and hemostasis. Semin Thromb Hemost 2018; 44 (04) 307-311
- 51 Favaloro EJ, Lippi G. Editorial compilation VI. Semin Thromb Hemost 2019; 45 (01) 5-9
- 52 Favaloro EJ, Lippi G. Editorial compilation VII. Semin Thromb Hemost 2019; 45 (05) 429-432
- 53 Kwaan HC, Lindholm PF. Emerging paradigms of thrombosis and cancer (part I): the yin yang relationship between thrombosis and cancer. Semin Thromb Hemost 2019; 45 (04) 319-320
- 54 Kwaan HC, Teruya J. Perturbation of hemostatic function by nonbiologic surfaces. Semin Thromb Hemost 2018; 44 (01) 5-6
- 55 Preston RJS, Lisman T. Extrahemostatic functions of platelets and coagulation factors. Semin Thromb Hemost 2018; 44 (02) 89-90
- 56 Favaloro EJ, Lippi G. Editorial compilation V. Semin Thromb Hemost 2018; 44 (03) 193-196
- 57 Schulman S. Recent advances in thrombosis and hemostasis—part III. Semin Thromb Hemost 2018; 44 (04) 312-314
- 58 Kwaan HC, Lindholm PF. Emergent paradigms of thrombosis and cancer (Part II): more on thrombosis and cancer. Semin Thromb Hemost 2019; 45 (06) 557-558
- 59 Rabbolini DJ, Othman M. Molecular and genetic testing in thrombosis and hemostasis. Semin Thromb Hemost 2019; 45 (07) 657-660
- 60 Favaloro EJ. A tribute to Eberhard F. Mammen, M.D. (1930-2008). Semin Thromb Hemost 2008; 34 (08) 703-707
- 61 Favaloro EJ. A short history of thrombosis and hemostasis: part I (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (05) 521-525
- 62 Favaloro EJ. A short history of thrombosis and hemostasis: part II (40th year celebratory issue). Semin Thromb Hemost 2014; 40 (08) 826-830